studies

504A AASLD ABSTRACTS HEPATOLOGY, October, 2015
level in the LPS-treated mouse liver, primary Kupffer and RAW
cells as compared with controls, whereas UBC9 mRNA level
decreased minimally. Phos-tagÔ SDS-PAGE showed that LPS
increased UBC9 phosphorylation in mouse liver and primary
Kupffer cells. These results support a potential key mechanism
for LPS that induces pro-inflammatory cytokines through lowering
UBC9 expression, raising its phosphorylation. Conclusions:
The novel finding that LPS lowers UBC9 protein level has
important implications since this facilitates the pro-inflammatory
response. A better understanding of molecular mechanisms on
how LPS treatment influences sumoylation-regulated cytokines
in Kupffer cells, will open a crucial area of investigation providing
new targets for therapy in alcoholic liver diseases.
Disclosures:
The following authors have nothing to disclose: Maria Lauda Tomasi, Komal
Ramani, Minjung Ryoo
595
A comparative analysis of the Spanish and Latin-American
prospective drug-induced liver injury (DILI) networks
Fernando Bessone 1 , Nelia Hernández 2 , Adriana Sanchez Ciceron
2 , Maria Di Pace 2 , Gisela Gualano 3 , Marco Arrese 4 , Alex Ruiz 4 ,
Aurora Loaeza del Castillo 5 , Marcos A. Girala 6 , Enrique Carrera 7 ,
Maribel Lizarzábal 8 , Edgardo Mengual 8 , Javier Brahm 9 , Juan P.
Arancibia 9 , Federico C. Tanno 1 , Milagros B. Davalos-Moscol 10 ,
Raymundo Paraná 11 , M I. Schinoni 11 , Nahum Méndez-Sanchéz 12 ,
Miguel E. Garassini 13 , Rodrigo L. Zapata 14 , I. Medina-Cáliz 15 ,
Andrés González-Jiménez 15 , Mercedes Robles Diaz 15 , C. Stephens
15 , A. Ortega 15 , Judith Sanabria 15 , Miren García-Cortés 15 ,
B. Garcia-Muñoz 15 , M. I. Lucena 15 , Raul J. Andrade 15 ; 1 Hospital
Provincial del Centenario, Rosario, Argentina; 2 Hospital de
Clínicas, Montevideo, Uruguay; 3 Hospital Posadas, Buenos Aires,
Argentina; 4 Pontificia Universidad Católica de Chile, Santiago,
Chile; 5 Instituto Nacional de Ciencias Médicas y Nutrición “Salvador
Zubirán”, Hospital General de México, Ciudad de Mexico,
Mexico; 6 Hospital de Clínicas, Asunción, Paraguay; 7 Hospital de
Especialidades Eugenio Espejo, Quito, Ecuador; 8 Hospital Universitario
de Maracaibo, Maracaibo, Venezuela, Bolivarian Republic
of; 9 Hospital Clínico Universidad de Chile, Santiago, Chile;
10 Hospital Rebagliati, Facultad de Medicina, Universidad San
Martin de Porres, Lima, Peru; 11 Hospital Universitario Prof. Edgard
Santos, Universidad Federal da Bahía, Salvador de Bahía, Brazil;
12 Fundación Clínica Médica Sur, Ciudad de Mexico, Mexico;
13 Hospital Universitario de Caracas, Caracas, Venezuela, Bolivarian
Republic of; 14 Universidad de Chile, Clínica Alemana de
Santiago, Santiago, Chile; 15 Instituto de Investigación Biomédica
de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria,
Universidad de Málaga, CIBERehd, Málaga, Spain
Background: DILI characteristics concerning phenotype and
involved drugs or other toxic compounds can vary between
individuals and possibly between different geographic populations.
We aimed to compare all DILI cases included in the
ongoing Spanish and Latin-American DILI Network that share
the same inclusion criteria and operational procedures. Material
and methods: Demographics, clinical parameters and
causative agents were compared between 200 Latin-American
and 867 Spanish DILI cases. Results: The mean age of DILI
development differed between the two registries with 51 years
in LatinAmerica and 54 years in Spain (p=0.02). Females predominated
among the LatinAmerican cases (59%) compared
to the Spanish cases (49%) (p=0.01). Duration of treatment
and time to onset were higher in LatinAmerican cases (127 vs
88 days, p